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Mild impairments in cognition in
patients with type 2 diabetes
mellitus: the use of the concepts
MCI and CIND
Type 2 diabetes mellitus (DM2) is associated
with moderate cognitive impairment in ver-
bal memory, mental flexibility, and informa-
tion processing speed, while other cognitive
functions remain relatively unaffected.1
Moreover, epidemiological studies have
shown that DM2 patients have a twofold
increased risk of developing either vascular
dementia or Alzheimer’s disease.1 2 In the
present study we examined whether mild
cognitive impairment (MCI) and ‘‘cognitive
impairment, no dementia’’ (CIND)—two
concepts that are used to describe cognitive
impairment in the transitional state between
normal aging and early dementia—can be
applied to the cognitive impairments encoun-
tered in a population based sample of DM2
patients. Recently, these concepts have
attracted considerable attention, as indivi-
duals who meet the criteria for either MCI or
CIND are known to have a substantially
increased risk of developing dementia.3 4
MCI is defined as a memory deficit without
impairments in other cognitive domains.3
Patients with MCI develop Alzheimer’s dis-
ease at an annual incidence of between 6%
and 25%, compared with 0.2–3.9% in the
general population of the same age. The
broader concept of CIND is used to describe
more general cognitive impairments, often
encountered in relation to vascular risk
factors. The diagnosis requires impairment
in one or more cognitive domains and no
dementia.5 A fivefold increased risk of devel-
oping Alzheimer’s disease, vascular demen-
tia, or mixed Alzheimer/vascular dementia
has been reported in patients with CIND.4 If
either of the concepts MCI or CIND is found
to be useful in describing the cognitive
problems in DM2, it may help identify DM2
patients who are at increased risk of devel-
oping dementia.
Participants were recruited for the Utrecht
diabetic encephalopathy study, which
assesses the impact of macrovascular and
microvascular disease on cognition in DM2.
This research was approved by the medical
ethics committee of the University Medical
Centre Utrecht. Patients (n=90) were aged
between 60 and 75 years, were known to
have had DM2 for at least one year, and were
recruited through their general practitioner.
Age and education matched control partici-
pants (n=40) were recruited through the
patient (mostly spouses) (table 1). Exclusion
criteria were a psychiatric or neurological
disorder (unrelated to DM2) that could
influence cognitive functioning, a history of
alcohol or substance abuse, and dementia. All
participants were functioning independently
at home and had intact comprehension of the
Dutch language. The participants had an
extensive neuropsychological examination
(11 tasks) addressing the following cognitive
domains in both a verbal and a non-verbal
form: abstract reasoning, memory, working
memory, information processing speed,
visuo-construction, attention, and mental
flexibility.
Previous studies used variable case defini-
tions of CIND and MCI, often based on the
diagnostic opinion of experienced clinicians.
We preferred a numerical approach, compar-
ing test scores with available age and educa-
tion adjusted normative data. This procedure
results in an objective classification and
facilitates comparison of different studies.
Performance of the participants on each test
was rated as either within the normal range
(0), below average (1), or impaired (2).
‘‘Normal performance’’ was defined as per-
formance between 21 SD and +1 SD from
the normative mean, ‘‘below average’’ as
between 21 SD and 21.65 SD from the
normative mean (the lowest 16% of the
normal population), and ‘‘impaired’’ as below
21.65 SD from the normative mean (the
lowest 5% of the normal population).
Performance on a cognitive domain as a
whole was classified as impaired when the
average rating of tests in that domain was
.1.
Participants were classified as having CIND
if they were impaired in one or more of the
cognitive domains.5 When memory was the
only affected domain, the participant was
also classified as having MCI, applying the
Petersen criteria.3 As a decrease in informa-
tion processing speed is common in an
elderly population, impairment in this
domain had to be accompanied by a rating
of 1 or 2 in more than half the tasks in
another domain (average rating of tests in
that domain .0.5) for the individual to be
classified as CIND.
Overall, the number of tasks on which
performance was impaired was higher in
DM2 patients than in controls (patients: five
tasks, interquartile range two to eight; con-
trols: two tasks, interquartile range one to
five; Mann–Whitney U test, p,0.05). The
domains that were affected most often in
both groups were mental flexibility (patients
11%; controls 10%) and information proces-
sing speed (patients 17%; controls 11%).
Memory was relatively spared (patients 4%;
controls 3%). Significantly more patients
than controls met the criteria for CIND (x2
test, p,0.05; table 1). The proportion of
participants classified as having MCI did
not differ between the two groups. In
addition, hypertension, major vascular events
(excluding non-invalidating stroke), retino-
pathy, and neuropathy were more common
in the DM2 patients (table 1). Within the
DM2 group no significant differences were
found between the patients with or without
CIND for age, diabetes duration, HbA1c, or
any of the factors described above. The same
applied for the controls with or without
CIND.
Comment
The results show that DM2 patients overall
had more cognitive impairments than control
participants, predominantly affecting mental
flexibility and information processing speed;
these cognitive domains are known to be the
most sensitive to cognitive decline associated
with aging. The prevalence of MCI and CIND
in the control group was comparable to
previous population based studies.3 5 CIND,
but not MCI, was significantly more common
in DM2 patients than in controls. Memory
impairment, which is the main feature of
MCI, was not the most prominent impair-
ment in the DM2 patients. Rather, a more
general pattern of cognitive impairment,
affecting multiple domains, was observed.
This pattern fits better within the broader
concept of CIND. These results illustrate that,
Table 1 Characteristics of the participants and the number and relative
frequencies of participants classified as having CIND or MCI
DM2 patients
(n = 90)
Controls
(n = 40) Statistics*
Demographic characteristics
Age (years) 66.8 (5.5) 65.2 (4.5) NS
Educational level (median, IQR) 4 (3 to 5) 4 (3 to 5) NS
Male sex 47 (52%) 18 (45%) NS
Estimated premorbid IQ 98.3 (16.9) 103.2 (15.2) NS
Impaired cognitive function
CIND 34 (38%) 8 (20%) p,0.05
MCI 2 (2%) 0 (0) NS
Medical characteristics
DM2 duration (years) 9.6 (6.5) – NA
Treatment
Diet 59 (65%) – NA
Oral medication 25 (28%) – NA
Insulin 6 (7%) – NA
HbA1c (%) 7.0 (1.2) 5.5 (0.3) p,0.05
Hypertension 67 (74%) 14 (35%) p,0.05
Non-invalidating stroke 5 (6%) 2 (5%) NS
Other major vascular events` 21 (23%) 3 (8%) p,0.05
Retinopathy1 29 (32%) 0 (0) p,0.05
Neuropathy 38 (42%) 7 (18%) p,0.05
Depression** 5 (6%) 0 (0) NS
Values are mean (SD) or n (%) unless specified.
*Between group comparisons for parametric data were done with t tests, for non-parametric data with
the Mann–Whitney U test, and for proportions with x2 tests.
Systolic pressure .160 mm Hg, diastolic pressure .95 mm Hg, or use of antihypertensive drug
treatment.
`Myocardial infarction and/or vascular surgery or endovascular intervention.
1Diabetic retinopathy severity scale as used in the Wisconsin epidemiological study of diabetic
retinopathy, cut off score 1.5.
Toronto clinical neuropathy scoring system, cut off score 5.
**Beck depression inventory, cut off score 16.
CIND, cognitive impairment, no dementia; DM2, type 2 diabetes; IQ, intelligence quotient; IQR,
interquartile range; MCI, mild cognitive impairment; NA, not applicable.
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because of its focus on memory impairments,
the concept of MCI should be used with
caution outside the field of Alzheimer’s
disease research. The concept of CIND
appears to be applicable more widely, but
its current broad and non-specific definition
remains a limitation. Thus the nature and
magnitude of the cognitive impairments
should also be taken into account when the
classification of CIND is used. Future pro-
spective studies, using clear criteria, should
resolve whether the concept of CIND could
serve to identify DM2 patients who are at
increased risk of developing dementia.
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Excessive daytime sleepiness in
migraine patients
Headache and sleep disorders are related in
several ways. Sleep disorders occur in head-
ache patients, headache is a common man-
ifestation of sleep disorders, and secondary
disorders may cause headache and sleep
complaints. Excessive daytime sleepiness
(EDS) or excessive somnolence is a common
symptom, with a prevalence of 10–20% in the
general population.1
EDS is a subjective feeling of a compelling
need for sleep at unusual times and in
abnormal environmental conditions. Sleep
deprivation, sleep fragmentation, and
hypoxia are believed to be the main mechan-
isms leading to EDS. EDS increases the risk of
car accidents, causes health status and
quality of life to deteriorate, and may increase
mortality. EDS is associated with obstructive
sleep apnoea syndrome, brain tumours, epi-
lepsy, stroke, degenerative diseases, trauma,
multiple sclerosis, and neuromuscular dis-
orders.1 The prevalence, mechanisms, impact,
diagnosis, and treatment of EDS have never
been assessed in migraine patients.
We studied 200 consecutive patients with
chronic or episodic migraine diagnosed
according to the second edition of the
International Headache Society diagnostic
criteria for migraine2 from the Jefferson
Headache Center, Philadelphia, USA . The
Epworth sleepiness scale (ESS)3 was applied
to all patients and correlated with the
diagnosis of chronic/episodic migraine, age,
sex, body mass index (BMI), and headache
frequency. Questions on mental and physical
fatigue, concentration, and memory problems
were rated using a 1 to 5 scale. The local
ethics committee approved the study. EDS
was defined as an ESS score of 10 or more.
Statistical analysis was done using the x2
and Fisher exact tests for proportions, and
Spearman and Pearson’s correlation tests.
The level of significance was set at p,0.05.
Demographic data are given in table 1.
Headache after dozing off was reported in
35% of all migraine patients (29% episodic,
40% chronic), and in 70% of patients with
EDS. The chance of dozing off in a car was
high in 1% of patients, moderate in 2%, and
slight in 15%. The ESS correlated with mental
fatigue, physical fatigue, concentration, and
memory complaints (p,0.05), but did not
correlate with BMI, age, or sex (NS). The
mean (SD) ESS was 8.4 (4.3). An ESS score
of 10 or more was present in 37% of all people
with migraine, in 32.4% of those with
episodic migraine, and in 39.8% of those
with chronic migraine. A score of 15 or more
was present in 10% of all migraine sufferers,
in 15.3% of those with chronic migraine, and
in 4.3% of those with episodic migraine
(p,0.05; table 1).
Comment
EDS is increasingly recognised as a signifi-
cant public health problem.1 It is common in
migraine compared with the general popula-
tion, with around a twofold increased pre-
valence in our migraineurs.
The risk of car accidents is assessed in
other medical disorders based upon daytime
sleepiness severity. Little attention has been
paid to the risk of car accidents in migraine
sufferers. EDS should be evaluated in this
population because of the risk of accidents in
those who report severe EDS.
EDS was correlated with fatigue in the
migraine patients in our study. Fatigue has
been reported in 85% of chronic migraine
sufferers, and was found to be very common
as a premonitory symptom in migraine.4
Understanding the causes of EDS in migraine
may shed light on the mechanisms of fatigue
in these patients
Dozing off was recognised as a headache
trigger in 35% of patients and in 70% of
patients with EDS. EDS may aggravate
migraine, and diagnosing and treating it
may lead to better outcomes.
Sleep loss or inadequate sleeping time is
the most common cause of EDS in the
general population. Primary sleep disorders—
such as sleep disordered breathing, restless
legs syndrome, and periodic leg movements
in sleep—are prevalent, particularly among
older people and may contribute to EDS.
Other medical conditions, such as cardiovas-
cular and pulmonary diseases, psychiatric
illness, chronic pain syndromes, and several
neurological and neurodegenerative disor-
ders, can disrupt sleep and lead to EDS.
Moreover, drugs including diuretics, antihy-
pertensives, sympathomimetic agents, corti-
costeroids, sedative-hypnotics, analgesics, and
certain antidepressants can cause EDS by
interfering with sleep continuity or by having
a direct sedating effect in the daytime.1
Can migraine lead to EDS, is EDS the
primary condition leading to migraine, or are
migraine and EDS determined by different
causes? All three possibilities may occur.
First, EDS may be an accompanying symp-
tom in migraine, and an increased EDS may
be a result of having migraine; the frequency
of migraine may also affect EDS, as our
chronic migraineurs scored higher. Second,
EDS may precipitate migraine attacks—in
our study dozing off was reported to be a
headache trigger in 35% of migraine patients
and in 70% of those with EDS. Third,
depression could be related to both migraine
and EDS, because it is comorbid with
migraine and can cause EDS. A control group
and the evaluation of depression and anxiety
symptoms would help to clarify the exact
relation between EDS and migraine.
We previously hypothesised a hypothala-
mic involvement in chronic migraine.5 The
hypothalamus is potentially the mediator of
EDS in migraine patients. Orexin, a recently
described neuropeptide, is thought to play a
role in the regulation of food intake, sleepi-
ness, autonomic nervous system activity,
and energy balance. Orexin containing
cells are located in the lateral hypothalamus,
with widespread projections to the entire
Table 1 Demographic data and
Epworth sleepiness scale in 200
patients with episodic and chronic
migraine
Demographic data
Age (years) 45 (12.5)
Sex (F/M) 162/38 (81%/19%)
BMI 27.8 (6.0)
Episodic migraine 72 (36%)
Chronic migraine 128 (64%)
Epworth sleepiness
scale
Mean (SD) score 8.4 (4.3)
Score 10 or more
All migraine 37%
Episodic migraine 32.4%
Chronic migraine 39.8%*
Score 15 or more
All migraine 10%
Episodic migraine 4.3%
Chronic migraine 15.3%
Values are mean (SD) or n (%).
*NS; p,0.05.
BMI, body mass index.
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